Auranofin

British Journal of Rheumatology

Volumn 36, Issue 5, 1997, Pages 560-572

  Kean, W F ^a   Hart, L ^a   Buchanan, W W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AURANOFIN;

BONE MARROW SUPPRESSION; CHEMISTRY; CONJUNCTIVITIS; DIARRHEA; HISTORY OF MEDICINE; HUMAN; LACTATION; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; RHEUMATIC DISEASE; STOMATITIS; THROMBOCYTOPENIA;

EID: 0030737962     PISSN: 02637103     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/36.5.560     Document Type: Review

References (111)

1. Wiegleb JC. Historisch-Kritische Untersuchung der Alchemie. Unveranderter Nachdruck der Originalausgable 1965;1777:185. Leipsig: Zentral-Antiquarit der Deutschen Demokratischen Republik.
2. Waley A. The way and its power: a study of the Tao teaching and its place in Chinese thought. London: Allen and Unwin, 1956.
3. Fung YL. A history of Chinese philosophy. Translated by Derk Bodde. 1952:Chapter 8. Princeton: Princeton University Press.
4. Exodus. The holy bible. Toronto: Oxford University Press, Chapter 32, Verse 20.
5. Pliny GP. Historia naturalis, book 33, as cited by Garrison FH. Introduction to the history of medicine, 4th edn. Philadelphia: WB Saunders, 1966:112.
6. Dioscorides P. De materia medica, cited by Garrison FH. Introduction to the history of medicine, 4th edn. Philadelphia: WB Saunders, 109-10.
7. Pattison Muir MM. Roger Bacon, his relations to alchemy and chemistry. In: Little AG, ed. Roger Bacon essays. New York: Russell and Russell, 1972:285-320.
8. Hunt LB. The Figuiers of Montpeller. Ambix 1979; 26:221-3.
9. Koch R. Uber Bacteriologische Forschung. Tenth International Medical Congress, Berlin. Dtsch Med Wochenschr 1980;16:756-7.
10. Forestier J. L'Aurothiopie dans les rhumatisme chronique. Bull Mem Soc Med Hop Paris, 1929;53: 323-7.
11. Puddephatt RJ. The chemistry of gold. New York: Elsevier, 1978:1.
12. Mohide TP. Gold. Ontario Ministry of Natural Resources, Mineral Policy Background Paper No. 12, 1981;246-52.
13. Pearson RG. Hard and soft acids and bases. J Am Chem Soc 1973;85:3533-9.
14. Sadler PJ. The comparative evaluation of the physical and chemical properties of gold compounds. J Rheumatol 1982;9:71-8.
15. Elder RC, Eidsness MK, Heeg MJ, Tepperman KG, Shaw CF, Schaeffer N. Gold-based antiarthritic drugs and metabolities. Am Chem Soc Symp Ser 1983; 209:385-90.
16. Shaw III FC. The mammalian biochemistry of gold: An inorganic prospective of chrysotherapy. Inorganic Perspect Biol Med 1979;2:287-355.
17. Blocka AK. Auranofin versus injectable gold. Comparison of pharmacokinetic properties. Am J Med 1983;75:114-22.
18. 195Au-labelled aurothiomalate in blood. Arthritis Rheum 1974;17:171-83.
19. Tepperman K, Finer R, Donovan S et al. Intestinal uptake and metabolism of auranofin, a new oral gold-based antiarthritis drug. Science 1984;225:430-2.
20. Intoccia AP, Flanagan TL, Walz DT et al. Pharmacokinetics of auranofin in animals. J Rheumatol 1982;9: 90-8.
21. Kean WF, Lock CJL, Howard-Lock H. Gold complex research in medical science. Difficulties with experimental design. Inflammopharmacology 1991;1:103-14.
22. Walz ET, Dimartino MJ, Griswold DE, Intoccia AP, Flanagan TL. Biologic actions and pharmacokinetic studies of auranofin. Am J Med 1983;75:90-108.
23. Walz DT, DiMartino MJ, Juch JH, Zuccarello W. Adjuvant-induced arthritis in rats. I. Temporal relationship of physiological, biochemical and haematological parameters. Proc Soc Exp Biol Med 1971;136:907-10.
24. Kean WF, Kassam YB, Lock CJL et al. Antithrombin activity of gold sodium thiomalate. Clin Pharmacol Ther 1984;35:627-32.
25. Salmerton G, Lipsky PE. Effect of gold compounds on human mononuclear phagocyte function. In: Schattenkirchner M, Muller W, eds. Modern aspects of gold therapy. Basel: Karger, 1983:63-74.
26. Percy JS, Davis P, Russell AS, Brisson E. A longitudinal study of in vitro tests for lymphocyte function in rheumatoid arthritis. Ann Rheum Dis 1978;37:416-20.
27. Lorber A, Simon T, Leeb J et al. Chrysotherapy. Suppression of immunoglobulin synthesis. Arthritis Rheum 1978;21:785-91.
28. Simon TM, Kunishmia DH, Biert GJ, Lorber A. Inhibitory effects of a new oral gold compound on HeLa cells. Cancer 1978;44:1865-75.
29. Crooke ST. A comparison on the molecular pharmacology of gold and platinum complexes. J Rheumatol 1982;9:61-70.
30. Van Riel PL, Gribnau FW, Van De Putte LB, Yap SH. Loose stools during auranofin treatment: clinical study and some pathogenic possibilities. J Rheumatol 1983;10:222-6.
31. Bandilla KK, Delattre M, Rahn B, Missler B. Long-term treatment of rheumatoid arthritis with auranofin: clinical results with auranofin from German and international studies which included a comparison of once and twice daily treatment. In: Capell HA, Cole DS, Manghani KK, Morris RW, eds. Auranofin. Amsterdam: Excerpta Medica, 1983:97-14.
32. Rangachari PK, Kean WF. Gold and D-penicillamine and the gastrointestinal tract. Clin Rheumatol 1989: 3:411-23.
33. Van Riel PLCM, Van de Putte LBA, Gribnau FWJ et al. A single-blind comparative study of auranofin and gold thioglucose in patients with rheumatoid arthritis. In: Capell HA, Cole DS, Manghoni KK, Morris RW, eds. Auranofin. Excerpta Medica, 1983:135-46.
34. Behrens R, Devereaux M, Hazeleman B et al. Investigation of auranofin-induced diarrhoea. Gut 1986;27:59-65.
35. Nagler J, Paget SA. Non-exudative diarrhoea after gold salt therapy: Case report and review of the literature. Am J Gastroenterol 1983;78:12-4.
36. + and fluid in the rat. J Pharm Pharmacol 1986;38:466-8.
37. Fondacaro JD, Henderson LS, Hardcastle PT et al. Effects of auranofin (SKwF 39162) on water and electrolyte flux in canine small bowel: A possible diarrhoegenic mechanism. J Rheumatol 1986;13:541-6.
38. Ammon HV, Fowle SA, Cunningham JA, Komorowski RA, Loeffler RF. Effects of auranofin and myochrysine on intestinal transport and morphology in the rat. Gut 1987;28:829-34.
39. De Beaux A, Keenan CM, Tytgat K, Rangachari PK. Responses of the colonic epithelium to auranofin: evidence for involvement of enteric nerves. J Rheumatol 1990;9:1137-41.
40. Rangachari PK, McWade D. Epithelial and mucosal preparations of canine proximal colon in Ussing chambers: comparison of responses. Life Sci 1986; 38:1641-52.
41. Snyder RG, Traeger C, Kelly L. Gold therapy in arthritis: observations in 100 cases treated with gold sodium thiosulphate and aurocein. Ann Intern Med 1939;12:1672-81.
42. Whittle BJR, Vane JR. Prostanoids as regulators of gastrointestinal function. In: Johnson LR, ed. Physiology of the gastrointestinal tract, 2nd edn. New York: Raven Press, 1987:143-80.
43. Powell DW. Intestinal water and electrolyte transport. In: Johnson LR, ed. Physiology of the gastrointestinal tract, 2nd edn. New York: Raven Press, 1987:1267-305.
44. Morris RW, Cole DS, Horton J, Hever MA, Pietrusko RG. Worldwide clinical experience with auranofin. Clin Rheumatol 1984;3(suppl. 10):105-12.
45. Ward JR, Williams NJ, Egger MJ et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1983;26:1303-15.
46. Kean WF, Anastassiades TP. Long term chrysotherapy. Incidence of toxicity and efficacy during sequential time periods. Arthritis Rheum 1979;22:495-501.
47. Kean WF, Bellamy N, Brooks PM. Gold therapy in the elderly rheumatoid patient. Arthritis Rheum 1983;26: 705-11.
48. Co-operating Clinics Committee. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973;16:353-8.
49. Furst D, Levine S, Srinivasan R et al. A double-blind trial of high versus conventional dosages of gold salts for rheumatoid arthritis. Arthritis Rheum 1977;20: 1473-80.
50. Tornrot T, Skrifvars B. Gold nephropathy prototype of membranous glomerulonephritis. Am J Pathol 1974; 75:573-84.
51. Merle LJ, Reidenberg MM, Camacho MT, Jones BR, Drayer DE. Renal injury in patients with rheumatoid arthritis treated with gold. Clin Pharmacol Ther 1980;28:216-22.
52. Panayi GS, Wooley P, Batchelor JR. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J 1978;2:1326-8.
53. Kelton JG, Carter CJ, Rodger C. The relationship between platelet-associated IgG, platelet life-form and reticuloendothelial cell function. Blood 1984;63:1434-8.
54. Howell A, Gumpel JM, Watts RWE. Depression of bone marrow colony formation in gold induced neutropenia. Br Med J 1975;1:432-4.
55. Bellelli A, Veneziani M, Tumiati B. Felty's syndrome: long term followup after treatment with auranofin. Arthritis Rheum 1987;30:1057-61.
56. Job-Deslandre C, Menkes CJ. Treatment of Felty's syndrome with auranofin and methylprednisolone. Arthritis Rheum 1989;32:1188-9.
57. Heur MA, Morris RW. Smith Kline & French worldwide clinical experience with auranofin: A review. In: Capell HA, Cole DS, Manghani KK et al., eds. Auranofin: proceedings of a Smith Kline & French international symposium. Amsterdam: Excerpta Medica, 1983:474-503.
58. Miyamato TS et al. Gold therapy in bronchial asthma - special emphasis on blood levels of gold and its teratogenicity. J Jpn Soc Intern Med 1974;63:1190-7.
59. Rogers JG et al. Possible teratogenic effect of gold. Aust Paediatr J 1980;16:194-5.
60. Cohen DL, Orzel J, Taylor A. Infants of mothers receiving gold therapy. Arthritis Rheum 1981;24:104-5.
61. Tarp U, Graudal H. A follow up study of children exposed to gold in utero. Arthritis Rheum 1985;28: 235-6.
62. Rocker I, Hendeson MJH. Transfer of gold from mother to foetus. Lancet 1976;2:1246.
63. Richards, AJ. Transfer of gold from mother to foetus. Lancet 1977;1:99.
64. Ostensen M, Husby G. Anti-rheumatic drug treatment during pregnancy and lactation. Scand J Rheumatol 1985;14:1-7.
65. Brooks PM, Kean WF, Buchanan WW. The clinical pharmacology of anti-inflammatory agents. London: Taylor and Francis, 1986:91-7.
66. Blau S. Metabolism of gold during lactation. Arthritis Rheum 1973;16:777-8.
67. Ostensen M, Skavdal K, Myklebust G et al. Excretion of gold in human breast milk. Eur J Clin Pharmacol 1986;31:261.
68. Davis P, Barraclough D. Interaction of D-penicillamine with gold salts. Arthritis Rheum 1977;20:1413-8.
69. Kean WF, Lock CJL. Penicillamine does not chelate gold (I). J Rheumatol 1983;10:527-30.
70. Hart LE, Tugwell P. The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis. Postgrad Med J 1989;65:905-12.
71. Iannuzi L, Dawson N, Zein N et al. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N Engl J Med 1983;309:1023-8.
72. Anderson J, Felson DT, Meenan RF, Williams HJ. Which traditional measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1989;32:1093-9.
73. Scott DL, Coulton BL, Bacon PA, Popert AJ. Methods of x-ray assessment in rheumatoid arthritis: A re-evaluation. Br J Rheumatol 1985;24:31-9.
74. Hart LE. Arthritis. In: Basmajian JV, Banerjee SN, eds. Clinical decision making in rehabilitation: efficacy and outcomes. Churchill Livingstone, New York. 1996:203-22.
75. Moher D, Jadad AR, Nichol G et al. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Controlled Clin Trials 1995;16:62-73.
76. Sackett DL, Haynes RB, Guyatt GH, Tugwell P (eds) Clinical epidemiology. A basic science for clinical medicine, 2nd edn. Boston: Little Brown, 1991.
77. MacPherson DW. Evidence-based medicine. Can Commun Dis Rep 1994;20:145-7.
78. Sackett DL. Rules of evidence and clinical recommendations. Can J Cardiol 1993:9:487-9.
79. Sutton BM, McGustry E, Waltz DT, Dimartino MJ. Oral gold. Antiarthritic properties of alkylphosphine gold coordination complexes. J Med Chem 1972; 15:1095-8.
80. Walz DT, Dimartino MJ, Sutton BM, Misher A. S K & F 36914 - an agent for oral chrysotherapy. J Pharmacol Exp Ther 1972:181:292-7.
81. Walz DT, Cimartino MJ, Chakrin LW, Sutton BM, Misher A. Antiarthritic properties and unique pharmacologic profile of a potential chrysotherapeutic agent: S K & F D-39162. J Pharmacol Exp Ther 1976;197: 142-52.
82. Finkelstein AE, Walz DT, Batista V et al. Auranofin. New oral gold compound for the treatment of rheumatoid arthritis. Ann Rheum Dis 1976;35:251-7.
83. Homma M, Abe T, Akizuki M et al. Interim results of a multicenter open study with auranofin in Japan. J Rheumatol 1982;9:160-8.
84. Bandilla K, Gross D, Gross W et al. Oral gold therapy with auranofin (SK&F 39162): A multicenter open study in patients with rheumatoid arthritis. J Rheumatol 1982;9:154-9.
85. Bernhard GC. Auranofin treatment for adult rheumatoid arthritis: Comparison of 2 mg and 6 mg daily dose. J Rheumatol 1982;9:149-53.
86. Calin A, Saunders D, Bennett R et al. Auranofin: 1 mg or 9 mg? The search for the appropriate dose. J Rheumatol 1982;9:146-8.
87. Weiss TE. Auranofin: Dose-related risk to benefit. Am J Med 1983;75:128-32.
88. Champion GD, Cairns DR, Bieri D et al. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. J Rheumatol 1988;15:28-34.
89. Katz WA, Alexander S, Bland JH et al. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis. J Rheumatol 1982;9:173-8.
90. Wenger ME, Alexander S, Bland JH, Blechman WJ. Auranofin versus placebo in the treatment of rheumatoid arthritis. Am J Med 1983;75(6A):123-7.
91. Bombardier C, Ware J, Russell IJ et al. Auranofin therapy and quality of life in patients with rheumatoid arthritis. Am J Med 1986;81:565-78.
92. Borg G, Allander E, Lund B et al. Auranofin improves outcome in early rheumatoid arthritis: Results from a 2-year, double blind, placebo controlled study. J Rheumatol 1988;15:1747-54.
93. Harth M, Davis P, Thompson JM et al. Comparison between sodium aurothiomalate and auranofin in rheumatoid arthritis: Results of a two-year open randomized study. Scand J Rheumatol 1987;16:177-84.
94. Smith PR, Brown GMM, Meyers OL. An open comparative study of auranofin vs. gold sodium thiomalate. J Rheumatol 1982;9:190-6.
95. Williams HJ, Dahl SL, Ward JR et al. One-year experience in patients treated with auranofin following completion of a parallel, controlled trial comparing auranofin, gold sodium thiomalate, and placebo. Arthritis Rheum 1988;31:9-14.
96. Davis P, Menard H, Thompson J et al. One-year comparative study of gold sodium thiomalate and auranofin in the treatment of rheumatoid arthritis. J Rheumatol 1985;12:60-7.
97. Rau R, Schattenkirchner M, Muller-Fassbender H et al. A three year comparative study of auranofin and gold sodium thiomalate in rheumatoid arthritis. Clin Rheumatol 1990;9:461-74.
98. Barraclough D, Brook A, Brooks P et al. A comparative study of auranofin, gold sodium thiomalate, and d-penicillamine in rheumatoid arthritis: A progress report. J Rheumatol 1982;9:197-200.
99. Felix-Davies DD, Stewart AM, Wilkinson BR et al. A 12-month comparative trial of auranofin and d-penicillamine in rheumatoid arthritis. Am J Med 1983; 75(6A): 138-41.
100. Hochberg MC. Auranofin or d-penicillamine in the treatment of rheumatoid arthritis. Ann Intern Med 1986;105:528-35.
101. Porter D, Madhok R. Hunter JA, Capell HA. Prospective trial comparing the use of sulphasalazine and auranofin as second line drugs in patients with rheumatoid arthritis. Ann Rheum Dis 1992;51:461-4.
102. Weinblatt ME, Kaplan H, Germain BF et al. Low-dose methotrexate compared with auranofin in adult rheumatoid arthritis: A thirty-six-week, double-blind trial. Arthritis Rheum 1990;33:330-8.
103. Williams HJ, Ward JR, Reading JC et al. Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis: A controlled clinical trial. Arthritis Rheum 1992;35: 259-69.
104. Felson DR, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990;33:1449-61.
105. Gofton JP, O'Brien WM. Effects of auranofin on the radiological progression of joint erosion in rheumatoid arthritis. J Rheumatol 1982;9:169-72.
106. Gofton JP, O'Brien WM, Hurley JN, Scheffler BJ. Radiographic evaluation of erosion in rheumatoid arthritis: Double blind study of auranofin vs placebo. J Rheumatol 1984;11:768-71.
107. Caruso J, Santandrea S, Sarzi Puttini P et al. Prevention of appearance of radiological lesions in early rheumatoid arthritis: A randomized, single-blind study comparing intra-articular rifamycin with auranofin. J Int Med Res 1992;20:61-77.
108. Lopez-Mendez A, Daniel WW, Reading JC et al. Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic disease program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis Rheum 1993; 36:1364-9.
109. Giannini EH, Brewer EJ, Person DA. Auranofin in the treatment of juvenile rheumatoid arthritis. J Rheumatol 1983;102:138-41.
110. Fraser TN. Gold treatment in rheumatoid arthritis. Ann Rheum Dis 1945;4:71-5.
111. Pincus T. Rheumatoid arthritis: Disappointing long-term outcomes despite successful short-term clinical trials. J Clin Epidemiol 1988;41:1037-41.